Company

Lilly

Pharmaceutical intelligence for Lilly with 20 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 18
Assets: 10

Recent signals(2)

StrategyJune 15, 2026

Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal

Lilly's Zepbound® is highlighted as the first prescription treatment for moderate-to-severe obstructive sleep apnea in adults with obesity.

ClinicalJune 15, 2026

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax regimen in previously treated CLL/SLL patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 15, 2026

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax regimen in previously treated CLL/SLL patients.